Amelioration of doxorubicin‑induced cardiotoxicity by resveratrol

Al‑Harthi,Sameer  E.; Alarabi,Ohoud  M.; Ramadan,Wafaa  S.; Alaama,Mohamed  N.; Al‑Kreathy,Huda  M.; Damanhouri,Zoheir  A.; Khan,Lateef  M.; Osman,Abdel‑Moneim  M.

doi:10.3892/mmr.2014.2384

Amelioration of doxorubicin‑induced cardiotoxicity by resveratrol

Authors:
- Sameer E. Al‑Harthi
- Ohoud M. Alarabi
- Wafaa S. Ramadan
- Mohamed N. Alaama
- Huda M. Al‑Kreathy
- Zoheir A. Damanhouri
- Lateef M. Khan
- Abdel‑Moneim M. Osman
View Affiliations

Affiliations: Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia, Department of Anatomy, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia, Cardiology Unit, Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia
Published online on: July 15, 2014 https://doi.org/10.3892/mmr.2014.2384
Pages: 1455-1460

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Doxorubicin (DOX), is a highly active anticancer agent, but its clinical use is limited by its severe cardiotoxic side‑effects associated with increased oxidative stress and apoptosis. Resveratrol (RSVL) is a naturally occurring polyphenolic compound (trans-3,5,4'-trihydroxystilbene) found primarily in root extracts of the oriental plant Polygonum cuspidatum and of numerous additional plant species. It has recently been shown that RSVL has a number of beneficial effects in different biological systems, which include anti-oxidant, antineoplastic, anticarcinogenic, cardioprotective and antiviral effects. In this study, we examined whether RSVL has protective effects against DOX‑induced free radical production and cardiotoxicity in male rats. The tested dose of DOX (20 mg/kg) caused a significant increase in the serum activities of the cardiac enzymes lactate dehydrogenase (LDH) and creatine phosphokinase (CPK) and the level of malondialdehyde (MDA) in the heart tissue. However, there was a significant decrease in the glutathione level in the heart tissue. Simultaneous treatment of rats with RSVL [10 mg/kg, intraperitoneal (i.p.) injection] reduced the activity of LDH and CPK and significantly reduced MDA production in the heart. The total antioxidant capacity was increased following RSVL administration. Electron microscopy examination of the heart tissue showed that DOX treatment results in massive fragmentation and lysis of the myofibrils, and that mitochondria show either vacuolization or complete loss of the cristae. Simultaneous treatment with RSVL ameliorated the effect of DOX administration on cardiac tissue, with cardiomyocytes appearing normal compared to the control samples, and mitochondria retaining their normal structure.

View Figures

View References

1	Lefrak EA, Pitha J, Rosenheim S and Gofottiebm JA: A clinicopathological analysis of adriamycin cardiotoxicity. Cancer. 32:302–314. 1973. View Article : Google Scholar
2	Singal PK and Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med. 339:900–905. 1998. View Article : Google Scholar : PubMed/NCBI
3	Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 43:460–472. 1983.PubMed/NCBI
4	Powis G: Free radical formation by antitumor quinones. Free Radic Biol Med. 6:63–101. 1989. View Article : Google Scholar : PubMed/NCBI
5	Olson RD and Mushlin PS: Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4:3076–3086. 1990.PubMed/NCBI
6	Ogura R, Sugiyama M, Haramaki N and Hidaka T: Electron spin resonance studies on the mechanism of adriamycin-induced heart mitochondrial damages. Cancer Res. 51:3555–3558. 1991.PubMed/NCBI
7	Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K and Young RC: Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 197:165–167. 1977. View Article : Google Scholar : PubMed/NCBI
8	Mimnaugh EG, Trush MA, Bhatnagar M and Gram TE: Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochem Pharmacol. 34:847–856. 1985. View Article : Google Scholar : PubMed/NCBI
9	Singal PK, Deally CM and Weinberg LE: Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 19:817–828. 1987. View Article : Google Scholar : PubMed/NCBI
10	Goswami SK and Das DK: Resveratrol and chemoprevention. Cancer Lett. 284:1–6. 2009. View Article : Google Scholar : PubMed/NCBI
11	Alkreathy H, Damanhouri ZA, Ahmed N, Slevin M, Ali SS and Osman AM: Aged garlic extract protects against doxorubicin-induced cardiotoxicity in rats. Food Chem Toxicol. 48:951–956. 2010. View Article : Google Scholar : PubMed/NCBI
12	Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V and Milner A: A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond). 84:407–412. 1993.PubMed/NCBI
13	Sugioka K and Nakano M: Mechanism of phospholipid peroxidation induced by ferric ion-ADP-adriamycin-co-ordination complex. Biochim Biophys Acta. 713:333–343. 1982. View Article : Google Scholar : PubMed/NCBI
14	Sparano JA: Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Semin Oncol. 25(Suppl 10): 66–71. 1998.PubMed/NCBI
15	Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 10:117–127. 1992.PubMed/NCBI
16	Li H, Xia N and Förstermann U: Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide. 26:102–110. 2012. View Article : Google Scholar
17	Danz ED, Skramsted J, Henry N, Bennett JA and Keller RS: Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med. 46:1589–1597. 2009. View Article : Google Scholar
18	Tatlidede E, Sehirli O, Velioğlu-Oğünc A, Cetinel S, Yeğen BC, Yarat A, Süleymanoğlu S and Sener G: Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res. 43:195–205. 2009. View Article : Google Scholar : PubMed/NCBI
19	Preus M, Bhargava AS, Khater AE and Günzel P: Diagnostic value of serum creatine kinase and lactate dehydrogenase isoenzyme determinations for monitoring early cardiac damage in rats. Toxicol Lett. 42:225–233. 1988. View Article : Google Scholar
20	Osman AM, Al-Shabanah OA and Al-Harbi MM: Effect of desferrioxamine on doxorubicin-induced cardiotoxicity and haematotoxicity in mice. Med Sci Res. 21:193–194. 1993.
21	Hemnani T and Parihar MS: Reactive oxygen species and oxidative DNA damage. Indian J Physiol Pharmacol. 42:440–452. 1998.PubMed/NCBI
22	Van Vleet JF, Ferrans VJ and Weirich WE: Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol. 99:13–42. 1980.PubMed/NCBI
23	Nagi MN and Mansour MA: Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. Pharmacol Res. 41:283–289. 2000. View Article : Google Scholar : PubMed/NCBI
24	Al-Majed AA, Gado AM, Al-Shabanah OA and Mansour MA: Alpha-lipoic acid ameliorates myocardial toxicity induced by doxorubicin. Pharmacol Res. 46:499–503. 2002. View Article : Google Scholar : PubMed/NCBI
25	Osman AM, Al-Harthi SE, Alarabi OM, Elshal MF, Ramadan WS, Alaama MN, Al-Kreathy HM, Damanhouri ZA and Osman OH: Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin-treated animals. Cancer Cell Int. 13:522013. View Article : Google Scholar : PubMed/NCBI
26	Singal PK and Pierce GN: Adriamycin stimulates low-affinity Ca²⁺ binding and lipid peroxidation but depresses myocardial function. Am J Physiol. 250:H419–H425. 1986.PubMed/NCBI
27	Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N and Sawyer DB: Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol. 26:3777–3784. 2008. View Article : Google Scholar : PubMed/NCBI